The risk is that, if the early results are amazing and some big pharma does like it, they'll just launch a cheap take over bid instead of bothering with partnering.
If a bio was to offer say $40m, that's 5x or 400% premium (almost unheard of), the company would likely be obligated to present it to shareholders, and with so many trapped holders they may just vote it through.
$40m or 2.5c takeover would leave many of us long term holders well underwater.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $15.69K | 3.919M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 21936206 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 24685267 | 27 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |